Sarilumab for Patients With Moderate COVID-19 Disease
Sarilumab for Patients With Moderate COVID-19 Disease
Objectives: To determine whether blockade of IL-6R is beneficial in patients with COVID-19
 infection of moderate severity.

 Research Design: Randomized, controlled trial. Two-arm trial comparing standard care alone to
 standard care with addition of sarilumab (anti-IL6R). The trial will use a randomized
 play-the-winner design, in which randomization becomes weighted toward the arm that was more
 effective in previous subjects in the trial.

 Methodology Hospitalized patients meeting clinical criteria for moderate disease and testing
 positive for coronavirus infection. Interventions: sarilumab, 400 mg subcutaneous injection.
 Standard care is not pre-specified, may vary among patients, and may include agents with
 anti-viral activity, such as remdesivir or hydroxychloroquine, among others. Up to 120
 patients, primary outcome intubation or death within 14 days. All data will be extracted
 remotely from the electronic health record (EHR).

 Clinical Implications: The study has potential to establish IL-6R blockade, delivered
 subcutaneously, as standard of care in reducing progression to critical illness in patients
 with moderate COVID-19 disease.
1. Aims/Objectives

 The effectiveness of blockade of IL-6R in treating patients with COVID-19 disease of
 moderate severity will be tested in a pragmatic and adaptive randomized trial. The
 primary outcome is intubation or death within 14 days of enrollment OR administration of
 a rescue dose of IL-6 inhibition if the patient is do-not-resuscitate
 (DNR)/do-not-intubate (DNI) and the primary team determines it is appropriate based on
 clinical deterioration. Secondary outcomes include time to hospital discharge if alive,
 time to clinical recovery as was defined in a recent study, ICU length of stay, time to
 return to normal or baseline oxygen saturation, and changes in laboratory biomarkers.

 2. Background Information

 SARS-COV-2 is a novel human pathogen that emerged at the end of 2019 and rapidly spread
 worldwide. Clinical disease caused by this novel infection has a high mortality rate,
 particularly in older adults and in patients with underlying cardiopulmonary disease,
 populations that are highly prevalent within the VA healthcare system. This creates an
 urgent need for the VA to quickly and efficiently identify effective therapies to reduce
 mortality and spread of the disease. Based on in vitro and in vivo data, potential
 treatment options include anti-viral drugs (such as antimalarials or medications
 originally developed to treat HIV infection (e.g., lopinavir/ritonavir, remdesivir)),
 anti-inflammatory drugs, including IL-6 inhibition, and innovations in supportive care,
 such as placing patients in prone positioning while awake and not intubated.
 Importantly, in the context of the global pandemic and exponential spread of the
 disease, clinical trials must be designed in a manner that 1) optimizes outcomes for
 Veterans, and 2) produces rapid answers, so that effective treatments can be deployed
 quickly to reduce unnecessary deaths. Based on a review of 384 ongoing clinical trials
 by the Centre for Evidence-Based Medicine, and a daily search of open clinical trials,
 many conventional controlled clinical trials of antiviral drugs and cytokine-blocking
 drugs are in progress and are likely to be completed within a few months; however, it is
 possible that these trials, which may take months to implement and report results, will
 not yield any information about how to treat patients until after the peak of the
 pandemic is over. A secondary challenge is that it is important to identify what works
 and what does not work quickly, so that manufacturers can understand what medications
 need to be produced so that supply chains are adequate for treating all patients who
 might benefit from an intervention. Thus, innovative clinical trial methodologies are
 needed in order to produce answers in a highly compressed time frame to inform medical
 decision-making and supply chain management.

 This novel and innovative proposal concerns use and comparison an existing drug
 (sarilumab) that blocks the receptor for the inflammatory cytokine IL-6. Most studies of
 IL-6 pathway blockade are using IV medications and include restrictive eligibility
 criteria and are directed towards patients with severe disease. The investigators
 hypothesize that patients earlier in the disease course - prior to severe respiratory
 decompensation - might benefit the most from IL-6 inhibition, and thus are the
 population included in this pragmatic trial. This study will expand our knowledge and
 understanding about how IL-6 inhibition can be used to prevent disease progression in
 patients with moderate disease. It will use a more readily available subcutaneous,
 longer-acting formulation directed towards patients with moderate disease, of whom
 25-35% can progress to severe disease, often rapidly. Eligibility criteria allow for a
 broad range of underlying choices of other medications, including antiviral medications
 such as remdesivir and hydroxychloroquine, among others, baseline laboratory values, and
 comorbidities, reflecting likely real-world clinical use. Thus, this pragmatic project
 would fill a major gap in research about the clinical care of patients with COVID-19.

 Release of preliminary results to the popular press already necessitated revision of
 this protocol after only 9 subjects had been enrolled. Interim analysis of a study of
 sarilumab by its manufacturer has led to revision of the study population and treatment
 arms. Originally, two doses (200 mg and 400 mg) were tested, and patients with either
 severe (oxygen requirement and other poor prognostic features) or critical (mechanical
 ventilation) disease were included. Interim analysis indicated benefit only with 400 mg
 in critical disease, so that will be the design of the remainder of that trial. In
 contrast, a study of of a relatively high dose of tocilizumab (8 mg/kg) was reported to
 be beneficial in a controlled trial of patients varying in severity from critical
 illness to merely requiring supplementary oxygen. In response, the current study has
 been modified to allow routine escalation of dosing among a broad range of "moderate"
 severity short of critical illness. For patients who are critically ill, it is expected
 that off-label use of a wide range of "heroic" therapies will be tried, including but
 not limited to cytokine blocking therapies, so exclusion of such patients from this
 trial does not limit the therapeutic options for such patients, and from a research
 perspective, such patients have become the focus of the largest ongoing study of
 sarilumab.

 3. Rationale and Purpose

 Severe COVID-19 disease is characterized by a severe acute respiratory distress syndrome
 (ARDS) followed by a severe cardiomyopathy in many cases. Based on currently available
 data, it is unclear how much of the respiratory damage in COVID-19 is due to direct
 effects of SARS-COV-2, or if the primary driver of severe disease is the inflammatory
 response generated in response to the virus. The key role of inflammation in the
 progression of the disease is highlighted by recent studies, which demonstrate that
 patients who progress to requiring ICU-level care no longer have detectable virus
 present in their respiratory tract. Thus, identifying drugs that could dampen the
 inflammatory response prior to severe clinical decompensation without adversely
 affecting clearance of virus would be clinically useful and lead to improved outcomes.
 Elevated biomarkers of severe inflammation (such as IL-6, CRP, ferritin, and
 lymphopenia) have been strongly associated with severe disease and increased mortality
 in patients with COVID-19, and early development of a strong IgG response may
 paradoxically be a poor prognostic sign during the acute phase of the disease. In
 contrast, viral load in upper respiratory secretions at baseline is only modestly
 associated with clinical outcomes, and viral load declines in most patients after
 presentation, independent of the clinical course of the disease. Severe disease
 typically arises more than 2 weeks after symptom onset, a time at which virus is usually
 no longer detectable. These findings suggest that progression to severe disease may be
 driven more by the inflammatory response to the disease than a direct viral effect, and
 point to anti-inflammatory drugs as potentially critical therapeutic options.
 Importantly, high dose glucocorticoids have been found to be ineffective in severe
 COVID-19 and are associated with somewhat worse outcomes, so other more targeted
 anti-inflammatory options are urgently needed.

 Blockade of IL-6 signaling is a particularly attractive approach. Sarilumab and
 tocilizumab are antibodies to the IL-6 receptor (IL-6R), FDA-approved for long-term
 treatment of rheumatoid arthritis. Tocilizumab has been used open-label with enough
 anecdotal success in enough patients in China that the manufacturers of sarilumab and
 tocilizumab have rapidly opened clinical trials in multiple countries at assess efficacy
 in patients with severe COVID-19 disease. Tocilizumab has also demonstrated efficacy in
 reducing mortality associated with the cytokine release syndrome in patients receiving
 CAR-T treatment for cancer, in which the pathogenic pathway is widespread T-cell
 activation, which leads to production of pleiotropic inflammatory cytokines such as IL-6
 by monocytes. Although trials attempting to rescue patients with severe COVID-19 with
 ARDS and/or cardiomyopathy are essential and are in progress, the ideal population for
 clinical use may be patients who are not yet critically ill but are at high risk of
 clinical deterioration due to secondary inflammation.

 4. Relevance to Veterans Health

 COVID-19 has a high mortality rate of 2-3% among symptomatic patients. It is expected to
 have a particularly high mortality in Veterans, because age >60, underlying
 cardiovascular or lung disease, and obesity are significant risk factors for mortality
 and clinical deterioration. Thus, advances in care of patients sick enough to be
 hospitalized yet prior to intubation are expected to have particular benefit for
 Veterans.

 5. Study Design

 Design. Prospective, randomized, unblinded interventional clinical trial.

 Two arms: standard care, based on established practices within the medical center, or
 standard care plus subcutaneous sarilumab.

 Assignment Strategy: Randomized play-the-winner design, such that randomization becomes
 weighted toward the arm that was more effective in previous enrolled subjects. The
 probability of randomization to a specific arm (standard of care or standard of care plus
 intervention) will be updated based on outcomes in blocks of 10-20 subjects (see Planned
 Statistical Analyses). The protocol does not include administration of sarilumab or
 tocilizumab as a "rescue" medication if a patient randomized to standard of care alone
 deteriorates to the point that the primary outcome (intubation) is met, or if the patient is
 DNR/DNI and the patient's primary clinical team determines intubation would be performed if
 the patient's goals of care included intubation. Such patients may receive any treatment per
 the judgment of their treating physician, and such treatment might include sarilumab or
 tocilizumab. Use of sarilumab or tocilizumab in this setting will simply be regarded as a
 treatment failure and not as a protocol deviation.

 Data will be extracted remotely from the EHR. No data will be generated specifically for
 study purposes.
Study subjects will be inpatients with confirmed SARS-CoV-2 testing. Testing is performed
 at the discretion of the treating physician. Only Veterans will be enrolled.

 Inclusion Criteria:

 1. Positive testing for novel coronavirus SARS-CoV-2019

 2. Patients with moderate COVID-19 disease as defined clinically:

 1. Score of 1-3 (out of 3) on a modified Brescia COVID respiratory severity score
 (BCRSS), elements of which include wheezing or inability to speak complete
 sentences without effort, respiratory rate ≥22, O2 saturation ≤ 94% with or
 without supplemental oxygen, or requiring ≥2L supplemental oxygen to maintain O2
 Sat >94% in patients without previously documented hypoxia or baseline
 oxygenation requirement; either is equal to one point on the score) all within a
 24-hour period prior to enrollment, and/or any worsening of chest X-ray (CXR)
 findings after COVID-19 diagnosis

 2. Worsening of baseline oxygenation by at least 3%, or increase in oxygen
 requirement by at least 2L, in patients with pre-existing hypoxemia or receiving
 supplemental oxygen chronically.

 3. The BCRSS risk calculation score is available at:
 https://www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm

 Exclusion Criteria:

 1. Critical disease, defined by need for mechanical ventilation

 2. Expected death within 48 hours

 3. Patients taking any of the following for chronic inflammatory diseases:
 glucocorticoids equivalent to prednisone > 10 mg/day (methylprednisolone > 8 mg/day,
 dexamethasone > 2 mg/day), a JAK inhibitor (tofacitinib, baricitinib, upadacitinib),
 or a biologic

 1. Use of chronic inhaled steroids is NOT an exclusion

 2. Current or recent short-term use of glucocorticoids for chronic conditions such
 as COPD or gout is NOT an exclusion.

 3. Current use of glucocorticoids for COVID-19 is NOT an exclusion

 4. Use of biologics for non-inflammatory diseases is NOT an exclusion

 4. Receipt of any IL-6 inhibitor within 3 months prior to enrollment in the trial

 5. Pregnancy, due to lack of fetal monitoring capabilities

 6. Patients enrolled in other interventional clinical trials, including for COVID-19.
 Patients enrolled in non-interventional studies or receiving non-FDA-approved drugs
 for compassionate use are not excluded.

 7. Patients whose goal of care is comfort measures only

 8. Inability to provide informed consent, or absence of a legally authorized
 representative to provide informed consent.

 9. Severe psychiatric disease that prevents compliance with typical medical care.

 10. Initial positive test for active infection with novel coronavirus SARS-CoV-2019 was >4
 weeks prior to current admission.